Dr. Rebecca C. Arend
Claim this profileUniversity of Alabama at Birmingham Cancer Center
Studies Cancer
Studies Tumors
17 reported clinical trials
34 drugs studied
Area of expertise
1Cancer
KRAS positive
Stage IV
NRAS positive
2Tumors
Stage IV
KRAS positive
HPV16 positive
Affiliated Hospitals
Clinical Trials Rebecca C. Arend is currently running
Carboplatin + Mirvetuximab
for Ovarian Cancer
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients will receive NACT with one cycle of carboplatin, followed by mirvetuximab + carboplatin (if FRα +) every 21 days for three cycles prior to interval cytoreductive surgery (iCRS). A total of 70 will be included in the study. Following completion of 4 cycles total of NACT and after allowing for appropriate recovery of cycle # 4, patients eligible for surgery, will undergo an iCRS. Patients will then complete 3 more cycles of mirvetuximab + carboplatin for a total of 7 intended cycles of treatment. It is up to the treating physician if they want to add bevacizumab to the last 2 cycles or use any type of maintenance therapy. The decision to add bevacizumab or use maintenance therapy does not need to be made upfront. Patients will sign a screening consent form prior to tissue biopsy. If a patient is found to be FRα negative, their treating physician can select the treatment they deem appropriate and the patient will be declared a screen failure. Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP inhibitors.
Recruiting1 award Phase 29 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Rebecca C. Arend
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Rebecca C. Arend has experience with
- Paclitaxel
- Binimetinib
- Olaparib
- Palbociclib
- Ipatasertib
- Selumetinib Sulfate
Breakdown of trials Rebecca C. Arend has run
Cancer
Tumors
Ovarian Cancer
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rebecca C. Arend specialize in?
Rebecca C. Arend focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved KRAS positive patients, or patients who are Stage IV.
Is Rebecca C. Arend currently recruiting for clinical trials?
Yes, Rebecca C. Arend is currently recruiting for 11 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Rebecca C. Arend has studied deeply?
Yes, Rebecca C. Arend has studied treatments such as Paclitaxel, Binimetinib, Olaparib.
What is the best way to schedule an appointment with Rebecca C. Arend?
Apply for one of the trials that Rebecca C. Arend is conducting.
What is the office address of Rebecca C. Arend?
The office of Rebecca C. Arend is located at: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States. This is the address for their practice at the University of Alabama at Birmingham Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.